Myeloma Patients Europe (MPE) held a webinar to summarise the most important myeloma and AL amyloidosis updates presented at the European Hematology Association (EHA) hybrid 2023 congress. This congress was held in Frankfurt, Germany, in…
Myeloma Patients Europe (MPE) has today launched a first-of-its-kind advocacy report on Addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE). The report, led by the MPE CEE Workgroup on Access, found huge…
From T-cell collection to CAR T-cell infusion Myeloma Patients Europe (MPE) has conducted four written interviews on CAR-T manufacturing to better understand various myeloma CAR-T therapies’ manufacturing processes and challenges. Four stakeholders have answered our questions, including…
Myeloma Patients Europe (MPE) will host a webinar to summarise the most important myeloma and AL amyloidosis updates presented at the congress on 6 July 2023, from 17:00 – 18:00 CET, given by Prof. Dr. Mohamad…
The European Hematology Association’s (EHA) annual congress, one of the most important haematology congresses here in Europe, is being held in Frankfurt, Germany from 8 June to 15 June 2023 in a hybrid format. Myeloma…
Job Title: Access and Policy Project Manager Position Type: Full time/permanent Location: Home-based in UK, Germany, France or Spain Travel required: 30 days / year (approx.) Gross salary: 35.000 – 40.000 EUR/year (30.000 – 34.000GBP/per year)…
Myeloma Patients Europe (MPE) is pleased to announce it has been appointed to the new Health Technology Assessment (HTA) Stakeholder Network of the European Commission. This means that MPE will be actively engaged and consulted…
As part of the Horizon 2020 CARAMBA project, Myeloma Patients Europe (MPE) interviewed experts on different aspects of the CARAMBA clinical trial: manufacturing process, safety updates, and immune monitoring. The videos were filmed during the…